Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis
Quantitative MR Imaging and Proton Spectroscopy in MS
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Magnetic Resonance Imaging
What it measured
Main measures
Assess the MS lesions using Magnetization transfer ratio histogram parameters and compare it to total brain parenchymal volume
5 years
Disability progressionMRI lesionsMyelin repair
Other measures (1)
Quantitative analysis of whole brain N-acetylaspartate (WBNAA)
5 years
Brain volume loss
Who could take part
MS (type not specified) · 7 to 110
Show the full criteria
Inclusion criteria
1. Patients with known MS diagnosis 2. Age 7-110 years 3. Males or females
Exclusion criteria
1. Medically unstable 2. Artificial implants in the body 3. Pregnant Normal Controls
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. Results will be compared to age matched controls. Investigators will assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests. Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years.
Papers
Loading reviews and guidelines…
History
Started
Aug 1991
Main results due
Apr 2016
Finished
Apr 2016